Severe covid-19 pneumonia has posed critical challenges for the research and medical
communities. Older age, male sex, and comorbidities increase the risk for severe disease …

During the coronavirus disease 2019 (COVID-19) pandemic, noninvasive respiratory
support has played a central role in managing patients affected by moderate-to-severe acute …

Introduction Hospitalised patients with coronavirus disease 2019 (COVID-19) as a result of
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have a high …

Background The utility of heated and humidified high-flow nasal oxygen (HFNO) for severe
COVID-19-related hypoxaemic respiratory failure (HRF), particularly in settings with limited …

Background The first wave of COVID-19 in South Africa peaked in July, 2020, and a larger
second wave peaked in January, 2021, in which the SARS-CoV-2 501Y. V2 (Beta) lineage …

Non-invasive respiratory support (NIRS) has increasingly been used in the management of
COVID-19-associated acute respiratory failure, but questions remain about the utility, safety …

Since the identification of SARS-CoV-2 at the end of 2019, the coronavirus disease 2019
(COVID-19) pandemic has affected more than 410 million people worldwide and killed …

In December 2019, a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
was discovered in Wuhan, China, the rapid spread of which culminated in a global …

Rationale In patients with COVID-19 pneumonia and mild hypoxaemia, the clinical benefit of
high-flow nasal oxygen (HFNO) remains unclear. We aimed to examine whether HFNO …

The first cluster of cases of COVID-19 pneumonia was reported on December 31, 2019.
Since then, this disease has spread rapidly across the world, and as of September 17, 2021 …